Antibody-drug conjugates (ADCs) have transformed oncology therapeutics by combining the selectivity of monoclonal antibodies with the potency of highly cytotoxic small-molecule drugs. Rongrong Li, senior principal scientist, WuXi AppTec discusses.
What ADC toxicity reveals about payload design
